Breakdown | TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 47.37B | 46.90B | 45.10B | 43.46B | 48.71B | 45.00B |
Gross Profit | 9.03B | 9.84B | 10.33B | 11.46B | 10.79B | 9.48B |
EBITDA | 6.06B | 7.92B | 9.08B | 9.88B | 9.04B | 8.56B |
Net Income | 2.65B | 3.29B | 3.60B | 4.67B | 4.25B | 3.94B |
Balance Sheet | ||||||
Total Assets | 79.63B | 77.71B | 70.55B | 64.94B | 57.74B | 54.25B |
Cash, Cash Equivalents and Short-Term Investments | 3.24B | 2.73B | 3.61B | 4.38B | 3.37B | 3.08B |
Total Debt | 11.32B | 8.72B | 4.96B | 3.45B | 3.39B | 3.37B |
Total Liabilities | 27.61B | 25.44B | 19.58B | 17.27B | 15.82B | 17.38B |
Stockholders Equity | 52.01B | 52.07B | 50.67B | 47.30B | 41.62B | 36.51B |
Cash Flow | ||||||
Free Cash Flow | -3.05B | -1.09B | -1.40B | -363.00M | -1.17B | 1.53B |
Operating Cash Flow | 1.84B | 5.18B | 4.16B | 4.37B | 5.18B | 4.31B |
Investing Cash Flow | -5.29B | -5.93B | -5.57B | -4.40B | -6.32B | -2.68B |
Financing Cash Flow | 3.96B | -183.00M | 616.00M | 989.00M | 1.42B | -350.46M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
73 Outperform | ¥29.85B | 14.04 | 3.51% | 8.07% | -45.20% | ||
71 Outperform | ¥26.90B | 7.51 | 5.54% | 4.00% | -0.03% | ||
70 Outperform | ¥34.52B | 10.84 | 7.01% | 2.83% | 13.46% | -46.40% | |
65 Neutral | ¥18.54B | 6.46 | 3.96% | 9.31% | -340.82% | ||
65 Neutral | ¥343.99B | 10.56 | -2.88% | 2.55% | 11.80% | -6.84% | |
56 Neutral | ¥23.76B | 83.32 | 3.00% | -2.24% | -92.72% |
Daito Pharmaceutical Co., Ltd. announced the repurchase of 105,200 of its own shares for 220,726,800 yen, conducted through market purchases on the Tokyo Stock Exchange in April 2025. This move is part of a broader strategy approved by the Board of Directors to repurchase up to 300,000 shares, aiming to enhance shareholder value and optimize capital structure.
Daito Pharmaceutical Co., Ltd. has revised its earnings forecast for the fiscal year ending May 31, 2025, due to lower than expected sales of high-value products and increased costs. Despite strong net sales, the company anticipates a decrease in operating, ordinary, and attributable profits, citing factors such as inventory valuation losses, higher outsourcing expenses, and increased R&D costs.
Daito Pharmaceutical Co., Ltd. reported a 5.6% increase in net sales for the nine months ending February 28, 2025, compared to the previous year. However, the company experienced a significant decline in profits, with operating profit down by 39.8% and ordinary profit by 34.9%. The financial results indicate challenges in maintaining profitability despite increased sales, which may impact the company’s strategic positioning and stakeholder confidence.